Navigation Links
UM researcher identifies novel treatment for pain in sickle cell disease
Date:7/22/2010

A University of Minnesota Medical School research team led by Kalpna Gupta, Ph.D., has discovered that cannibinoids offer a novel approach to ease the chronic and acute pain caused by sickle cell disease (SCD).

Using a mouse model of SCD, Gupta and University of Minnesota colleagues studied the pain mechanisms by observing animals that exhibited both musculoskeletal pain and temperature sensitivity, symptoms similarly experienced by humans with SCD. The team compared two classifications of drugs in their ability to manage pain sensed by the animals, the traditionally prescribed classification of drugs, opioids, with a new therapeutic approach, cannabinoids, a synthetic compound based on marijuana derivatives. Currently, the only approved treatment for management of severe pain in SCD is opioids.

Using confocal miscroscopy, a precise type of laser scanning that allowed the researchers to observe the nerve pathways of the animals, Gupta and her colleagues were able to study structural changes in the neural pathways that are activated when the animal is sensing pain. When comparing the effects that each classification of drug had on the animal's level of pain, Gupta discovered that both opioids and cannibinoids equally lessened the amount of pain the animals sensed. However, researchers were able to use much smaller doses of cannibinoids to achieve the same level of pain relief. Moreover, because researchers injected the cannibinoids directly into the body in such low doses, unwanted side effects that result from higher doses of the drug reacting in the brain were minimized.

"This paper provides proof that we can use other classifications of drugs to treat pain in patients with sickle cell disease," Gupta said. "Cannibinoids offer great promise in the treatment of chronic and acute pain, and they're effective in much lower amounts than opioidsthe only currently approved treatment for this disease."

Sickle cell disease is a genetic blood disorder that affects the red blood cells in the body making them become sickle-, or crescent-shaped. The crescent shape of the cells makes it difficult for them to pass through the small blood vessels in the body, forming blocks that lessen the flow of blood. The decreased blood flow often causes a variety of other serious health complications, including stroke and damage to vital organs including the lungs, spleen, kidneys, and liver.

The disease causes a constant level of chronic pain in patients, including cold and hot temperature sensitivity, and additional episodes of sharp, severe pain known as crises. Pain in SCD is described to be more intense than labor pain. The pain starts early in a patient's life, often during infancy, and increases in severity with age. There is no known cure, and the best treatment option for most patients with SCD is pain management. To date, the only approved classification of drugs for pain management and treatment of SCD is opioids (narcotics), the category of drugs that includes morphine. Opioids have long been used to manage the pain of patients with a variety of diseases, and the ill effects of the drugs are well known.

Particularly of concern for SCD patients is that opioids often negatively affect a patient's blood vessels and kidneys, two plaguing elements of the disease itself. In addition, patients with this disease need to take very high doses of opioids to sense any pain relief. Gupta and her team discovered that this is because the receptors required for the binding and action of morphine to provide pain relief are decreased in animals with SCD.


'/>"/>

Contact: Laura Stroup
lstroup@umn.edu
612-624-9912
University of Minnesota
Source:Eurekalert

Related biology news :

1. U of T researchers find link between childhood physical abuse and heart disease
2. Researchers use nanoparticles as destructive beacons to zap tumors
3. Researchers: EPA should recognize environmental impact of protecting foreign oil
4. LSU researchers secure NSF rapid response grants to study impact of oil spill
5. UT researchers: English ivy may give sunblock a makeover
6. K-State researchers find gene-silencing nanoparticles may put end to pesky summer pest
7. WSU researchers find way to make cancer cells more mortal
8. International AIDS Society and partners recognize outstanding researchers from around the world at AIDS 2010
9. LSU researcher looks for new ways to keep a dirty situation clean
10. Montana State researchers say Triceratops, Torsaurus were same dinosaur at different stages
11. CWRU dental researchers discover human beta defensins-3 ignite in oral cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology: